166 related articles for article (PubMed ID: 31283606)
1. Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer.
Ries M; Khreish F; Berchem G; Ezziddin S
Clin Nucl Med; 2019 Sep; 44(9):730-731. PubMed ID: 31283606
[TBL] [Abstract][Full Text] [Related]
2. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
3. Radioligand Therapy With
Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
[No Abstract] [Full Text] [Related]
4. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
5. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with
Afshar-Oromieh A; Haberkorn U; Zechmann C; Armor T; Mier W; Spohn F; Debus N; Holland-Letz T; Babich J; Kratochwil C
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):950-959. PubMed ID: 28280855
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
[TBL] [Abstract][Full Text] [Related]
7. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.
Awang ZH; Essler M; Ahmadzadehfar H
Radiat Oncol; 2018 May; 13(1):98. PubMed ID: 29792198
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for
Begum NJ; Thieme A; Eberhardt N; Tauber R; D'Alessandria C; Beer AJ; Glatting G; Eiber M; Kletting P
J Nucl Med; 2018 Jun; 59(6):929-933. PubMed ID: 29419479
[TBL] [Abstract][Full Text] [Related]
9. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
10. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Satapathy S; Mittal BR; Sood A
Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
[TBL] [Abstract][Full Text] [Related]
11. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
12.
Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
[TBL] [Abstract][Full Text] [Related]
13. Modeling and Predicting Tumor Response in Radioligand Therapy.
Kletting P; Thieme A; Eberhardt N; Rinscheid A; D'Alessandria C; Allmann J; Wester HJ; Tauber R; Beer AJ; Glatting G; Eiber M
J Nucl Med; 2019 Jan; 60(1):65-70. PubMed ID: 29748236
[TBL] [Abstract][Full Text] [Related]
14. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
Widjaja L; Derlin T; Ross TL; Bengel FM; Werner RA
Prostate; 2022 Jan; 82(1):86-96. PubMed ID: 34633090
[TBL] [Abstract][Full Text] [Related]
15. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
Ahmadzadehfar H; Essler M
J Nucl Med; 2018 Jul; 59(7):1033-1034. PubMed ID: 29653975
[No Abstract] [Full Text] [Related]
16. Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.
Derlin T; Werner RA; Lafos M; Henkenberens C; von Klot CAJ; Sommerlath Sohns JM; Ross TL; Bengel FM
J Nucl Med; 2020 Nov; 61(11):1602-1606. PubMed ID: 32169910
[TBL] [Abstract][Full Text] [Related]
17. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
18. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
19.
Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
[TBL] [Abstract][Full Text] [Related]
20. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
Ahmadzadehfar H; Albers P; Bockisch A; Boegemann M; Böhme C; Burchert W; Dietlein M; Drzezga A; Fabry U; Feldmann G; Heidenreich A; Heinzel A; Herrmann K; Heyll A; Höhling C; Kreuzer C; Laufer D; Mengel R; Mottaghy FM; Müller HW; Müller SC; Ost E; Rahbar K; Reifenhäuser W; Schäfers M; Schlenkhoff C; Schmidt M; Schmidt-Wolf I; Wildenhain C; Zimmer B; Essler M
Urologe A; 2018 Jun; 57(6):709-713. PubMed ID: 29671080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
